Company news

MannKind Corporation news in 2025

MannKind Corporation's news releases, calls and decks from 2025, newest first.

View company

MannKind Shares FUROSCIX® Business Updates

December 22, 2025

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

November 30, 2025

MannKind to Present at the Jefferies Global Healthcare Conference

November 10, 2025

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

November 9, 2025

MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes

November 5, 2025

MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update

November 4, 2025

MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

October 28, 2025

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

October 12, 2025

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

October 6, 2025

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

September 28, 2025

MannKind to Present at Upcoming Investor Conferences

August 26, 2025

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

August 26, 2025

MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

August 24, 2025

MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update

August 5, 2025

MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement

August 5, 2025

MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025

July 29, 2025

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23

June 8, 2025

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29

May 27, 2025

MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025

MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

April 30, 2025

MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options

April 6, 2025

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

March 9, 2025

MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

February 25, 2025

MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

February 18, 2025

MannKind Expands Executive Leadership Team

January 5, 2025

Calls in 2025

Decks in 2025